Wednesday, June 1, 2016
Celerion, a Lincoln, Neb.-based provider of early clinical research, has expanded laboratory capabilities to meet growing demand for cell-based assays. Assays involving whole cells provide a variety of measures of drug activity or effect that can be important endpoints in clinical research.
Celerion, a Lincoln, Neb.-based provider of cardiovascular safety services in early clinical research, has become a member of the Cardiac Safety Research Consortium (CSRC). Celerion will engage with other thought leaders on key issues that impact cardiovascular safety, including discussions of alternative approaches to ICH E14 to assess arrhythmia liability in early drug development.
Celerion, a provider of early clinical research, has expanded clinical operations to South Korea. Through a partnership with Seoul National University Hospital (SNUH), the new Asian office is located within the SNUH Clinical Trials Center, giving Celerion and its clients access to the 80-bed clinical research unit, particularly geared toward clinical pharmacology, oncology and pediatrics.
Celerion, a provider of innovative early stage drug development solutions based in Lincoln, Neb., has been awarded full accreditation by the Association for the Accreditation Human Research Protection Programs (AAHRPP), an independent, non-profit accrediting body. Celerion’s clinical facilities in Lincoln, Neptune, N.J. and Phoenix, Ariz., have achieved the milestone.